Safety and Efficacy of Piromelatine in Mild Alzheimer’s Disease Patients (ReCOGNITION)
Updated August 7, 2018
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.
For more information, please visit clinicaltrials.gov.
Neurim Pharmaceuticals Ltd.